The first patient in the USA has been treated with the bio-engineered dermo-epidermal skin transplant denovoSkin developed by CUTISS. The company explains in a corresponding press release that the four-year-old boy had experienced complex scarring and contractures after extensive burn wounds had healed. It added that the patient is already tolerating the two denovoSkin transplants well.
The skin transplant developed by CUTISS is bio-engineered from a small biopsy of healthy skin from the patient. This means that there is no need to take large areas of healthy skin from the patient for transplants. Unlike conventional cultured epithelial autografts, denovoSkin consists of not only an uppermost skin layer but also a bi-layer dermo-epidermal structure.
The surgery performed recently in the USA is more than just an application of technology according to a comment from Daniela Marino, CEO of CUTISS, in the press release. She added: “At CUTISS, we are dedicated to advancing treatments that can make a real difference in patients’ lives.” CUTISS was founded in 2017 as a spin-off from the University of Zurich and is located at Bio-Technopark Schlieren-Zürich. DenovoSkin, which CUTISS manufactures in Switzerland, has already been used for transplants in more than 60 patients from newborn babies to adults within the context of clinical trial in Europe. ce/hs
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space